TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Effective buprenorphine delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional impairment 3 months after stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Size of infarcts on follow-up CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of fatal parenchymal hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Cocaine abstinence for at least 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of solved Drug Related Problems (DRPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone-free rate after 1 treatment session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall success rate for SWL treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genotype GG association with TD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haplotype CGC association with TD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved erections
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neuropathy-specific quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Generic quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increase in 1RM all exercises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of change in VJ height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt (Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf (Area Under the Curve to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to TKIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extension of the uterine incision
Endpoint domain: Adverse events/effects
Primary endpoint: Number of heelsticks required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: syrinx resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of cerebrospinal fluid leak
Endpoint domain: Adverse events/effects
Primary endpoint: Survival from TBM
Endpoint domain: Mortality/survival
Primary endpoint: Positive change in attitudes and behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean exhaled nitric oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: early morning urinary cortisol-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in plaque elevation and scaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Successful interventional procedure with < 50% diameter stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in absolute SGTC seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: initial behavior change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of oral cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to accept an oral cancer screen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TKV slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: eGFR slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: composite endpoint of clinical progression events
Endpoint domain: Adverse events/effects
Primary endpoint: Increased intrahepatic triglycerides (IHTG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total obviously effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom scores of abdominal pain and related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CV composite outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of gastro-oesophageal reflux disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anxiety and depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Days off work
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: RVEF (Right Ventricular Ejection Fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RVSV (Right Ventricular Stroke Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RVEDV (Right Ventricular End-Diastolic Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary outcome achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CO(2) retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain experienced at hysteroscopy and endometrial biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of vasovagal reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient hopefulness for recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Surrogate preparation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thrombotic complications
Endpoint domain: Adverse events/effects
Primary endpoint: total volume of packed red cells transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: combined endpoint of heart failure hospitalization or all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Mean Harris hip score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clinical efficacy and safety of otamixaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive rate of serum p53‐Abs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general ill feelings/nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: indigestion/flatulence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean striatal SERT occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean striatal DAT occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dropout due to relapse or insufficient clinical response
Endpoint domain: Mortality/survival
Primary endpoint: acute exacerbation of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in asthma knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: enhancement of cognitive measures (attention and episodic memory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: increase in mismatch negativity (MMN) amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reduction of MMN latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perceived usefulness of CDSS/PDA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with CDSS/PDA
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of CDSS/PDA use in clinical setting
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence of Streptococci mutans to enamel surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colony number ratio of MS/TS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality rate at 10 months
Endpoint domain: Mortality/survival
Primary endpoint: mean ST resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ΔE values between selected color and actual color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRSday scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased risk of prostate cancer associated with Alu DNA methylation levels
Endpoint domain: Mortality/survival
Primary endpoint: learning effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: QRS complex voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Interventricular septal thickness (IVS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean blood concentrations of amphetamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhancement in psychomotor functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H-reflexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Startle reflexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: frequency of urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incontinence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: standardized gross motor quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gross motor quotient percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: locomotor skills score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median progression-free survival period
Endpoint domain: Mortality/survival
Primary endpoint: Global health scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Xerostomia-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function subscale scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: shoulder-girdle elevation force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surrogates' personal estimates of the patient's prognosis
Endpoint domain: Mortality/survival
Primary endpoint: surrogates' understanding of the physician's prognostic estimate
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in facial symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severity of paresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission to hospital in the latent stage of labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Use of narcotics during labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Admission of newborns to a level II observation nursery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Tumor necrosis factor α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total estrogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Bioavailable estrogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Major adverse cardiac event (MACE) occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Children's social-emotional development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Work participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Error rate in identifying the correct pen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DPN symptoms reduction on PGIC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in distal leg ENFD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postcesarean endometritis
Endpoint domain: Adverse events/effects
Primary endpoint: Time to DRR
Endpoint domain: Mortality/survival
Primary endpoint: mean difference in symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OR for new/worsening symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: OR for side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Poor global outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Exaggerated orthostatic fall in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain free status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: oral cleanliness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hs-CRP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific IgE reactivity to allergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CRP (C-Reactive Protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 (Disease Activity Score 28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac repolarization (ddQTc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decreased PHDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved mental health QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: improved physical QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in core temperature (T(core))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankylosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lifetime of the replanted teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure rates of emergency contraception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Decrease in ocular attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall efficacy evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean peak cTnI increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean peak CK increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentration of Icotinib (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Icotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (rash, increase in AST and ALT)
Endpoint domain: Adverse events/effects
Primary endpoint: VDD function maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of atrial undersensing
Endpoint domain: Adverse events/effects
Primary endpoint: Thrombin generation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Polymorphonuclear elastase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neuron-specific enolase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance during severe contrast reaction simulation scenario
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort in identifying and managing contrast reactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maintaining Viral Suppression (VS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean intrusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 embolic events
Endpoint domain: Adverse events/effects
Primary endpoint: Interval between RFO events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anxiety and depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in lip fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aesthetic improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cognitive functionality improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Headache response rates at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free response rates at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained pain-free response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of heart and ipsilateral lung treated to specified doses (20 Gy, 30 Gy, 40 Gy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiation dose outcomes
Primary endpoint: Dose heterogeneity within the target volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coverage of the IMN target volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rearrest rate
Endpoint domain: Mortality/survival
Primary endpoint: SAPS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 6-month change in total kcal/week energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 6-month change in kcal/week expenditure in moderate or vigorous activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lignocaine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lignocaine half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEGX area under the concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in flow‐mediated vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PCO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Current antidepressant use at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alerting attention scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TNF-alpha response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total number of inpatient hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: disability days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-corrected visual acuity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central macular thickness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of IVB injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vasoactive-inotropic score at ICU admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bioequivalence of imatinib formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Confidence (CPSIQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Sexual Performance (DPSIQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Volume of saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma aldosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes